Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[123I]beta-CIT SPECT in Parkinsonian Syndrome
NCT00117819Phase 2Completed
- Sponsor
- Institute for Neurodegenerative Disorders
- Start
- Mar 2001
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of [123I]beta-CIT in parkinsonian syndrome, sponsored by Institute for Neurodegenerative Disorders. Primary endpoint: Specific: Nondisplaceable striatal uptake ratio at 2 years. Started Mar 2001; status: completed.
02
Drugs
[123I]beta-CIT
03
Conditions
parkinsonian syndrome
Beyond the preview
Go deeper on NCT00117819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117819.